All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings
This article was originally published in Scrip
Executive Summary
Foreign currency exchange rates, generic competition and product sales (both good and bad) affected fourth quarter and full-year 2014 revenue and earnings for Bristol-Myers Squibb and Pfizer, but the companies assured investors on 27 January that their growth is dependent on what each of them sees as an improving research and development base.